New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareSurvodutide vs Vilon

Survodutide vs Vilon

Side-by-side comparison of key properties, dosing, and research.

GLP-1 / Weight Loss Agonists
Survodutide
Immune SupportAnti-Aging & Longevity
Vilon
Summary
Survodutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Phase 2 trials demonstrated up to 18.7% body weight reduction at 46 weeks, among the highest reported for a dual agonist. It is being studied for obesity and MASH (metabolic dysfunction-associated steatohepatitis), where the glucagon component drives hepatic fat clearance.
Vilon is a synthetic dipeptide (Lys-Glu) derived from the thymus gland extract Thymalin. The shortest immune-regulatory peptide known, Vilon modulates T-cell and NK-cell function, extends lifespan in animal models, and shows epigenetic anti-aging activity. It is one of the Khavinson peptide bioregulators.
Half-Life
~7 days
Very short as a free dipeptide; effects mediated via gene regulation
Admin Route
SubQ
SubQ, Oral
Research
Typical Dose
0.6 mg → 2.4 mg → 4.8 mg → 6 mg
1–2 mg SC daily or 5–10 mg oral daily
Frequency
Once weekly
Once daily
Key Benefits
  • Up to 18.7% body weight reduction at 46 weeks (Phase 2)
  • Strong MASH activity — Phase 3 SYNCHRONIZE-NASH trials ongoing
  • Reduces hepatic fat content via glucagon receptor-driven liver oxidation
  • Once-weekly subcutaneous injection
  • Greater weight loss potential than GLP-1 monotherapy
  • Improvements in liver fibrosis markers in early data
  • Immune system modulation and restoration
  • Lifespan extension (30–40% in animal studies)
  • T-cell and NK-cell activation
  • Epigenetic anti-aging activity
  • Reduces oxidative stress markers
  • Antioxidant gene upregulation
  • May prevent age-related immune senescence
  • Anti-tumor immune surveillance
Side Effects
  • Nausea (most common during titration)
  • Vomiting
  • Diarrhea
  • Decreased appetite
  • +3 more
  • Excellent safety profile, decades of Russian clinical use
  • Rare: mild injection site reaction
  • Very rare: mild allergic reaction
Stacks With